(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
5 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 11.62%
Live Chart Being Loaded With Signals
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox...
Stats | |
---|---|
Today's Volume | 225 996 |
Average Volume | 433 446 |
Market Cap | 80.28M |
EPS | $0 ( 2024-02-29 ) |
Next earnings date | ( $-0.210 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.970 |
ATR14 | $0.00200 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Kozin Marc D | Buy | 100 000 | Stock Option (Right to Buy) |
2024-03-20 | Kozin Marc D | Buy | 0 | |
2024-02-14 | Andriole Michael T. | Sell | 1 744 | Common Stock |
2024-02-14 | Laspaluto Michelle | Sell | 1 940 | Common Stock |
2024-02-14 | Jakeman David | Sell | 2 660 | Common Stock |
INSIDER POWER |
---|
88.93 |
Last 99 transactions |
Buy: 5 160 750 | Sell: 1 392 397 |
Volume Correlation
Chimerix Inc Correlation
10 Most Positive Correlations | |
---|---|
ALXO | 0.966 |
GXGX | 0.964 |
NAKD | 0.962 |
KNSA | 0.957 |
MICS | 0.956 |
CMLS | 0.956 |
BWB | 0.954 |
SIRI | 0.954 |
GOOD | 0.954 |
ORPH | 0.952 |
10 Most Negative Correlations | |
---|---|
PTOC | -0.971 |
MCFT | -0.969 |
LGAC | -0.964 |
APXI | -0.963 |
NVSA | -0.962 |
AGGR | -0.961 |
GFGD | -0.961 |
FRSG | -0.959 |
FTPA | -0.959 |
ACQR | -0.959 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Chimerix Inc Correlation - Currency/Commodity
Chimerix Inc Financials
Annual | 2023 |
Revenue: | $324 000 |
Gross Profit: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2023 |
Revenue: | $324 000 |
Gross Profit: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2022 |
Revenue: | $33.82M |
Gross Profit: | $33.38M (98.68 %) |
EPS: | $1.970 |
FY | 2021 |
Revenue: | $1.98M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.01 |
Financial Reports:
No articles found.
Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators